Pharsight

Drug Patents owned by Recordati Rare

1. List of Isturisa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835646 RECORDATI RARE Organic compounds
Aug, 2026

(3 years from now)

US8314097 RECORDATI RARE Organic compounds
Mar, 2029

(5 years from now)

US9434754 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8609862 RECORDATI RARE Use of an adrenal hormone-modifying agent
Jan, 2031

(7 years from now)

US10143680 RECORDATI RARE Pharmaceutical dosage forms
Jul, 2035

(12 years from now)

US10709691 RECORDATI RARE Pharmaceutical dosage forms
Oct, 2035

(12 years from now)

Do you want to check out ISTURISA patents from before 2022?
Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2025
Orphan Drug Exclusivity (ODE) Mar 6, 2027

Drugs and Companies using OSILODROSTAT PHOSPHATE ingredient

NCE-1 date: 2024-03-06

Market Authorisation Date: 06 March, 2020

Treatment: Cushing's disease

Dosage: TABLET;ORAL

More Information on Dosage

ISTURISA family patents

16

United States

8

Japan

7

European Union

5

China

5

Korea, Republic of

4

Spain

4

Mexico

3

Denmark

3

Poland

3

Canada

3

Singapore

EA

3

EA

3

Croatia

3

Cyprus

3

Peru

3

Israel

3

Portugal

3

Taiwan

3

Australia

3

Lithuania

3

Tunisia

3

Slovenia

3

Hungary

2

Philippines

2

Brazil

2

Morocco

2

Argentina

2

Norway

2

New Zealand

2

Chile

2

Ecuador

2

South Africa

IB

1

IB

1

Hong Kong

1

Malaysia

1

Turkey

1

RS

1

Russia

1

Ukraine

1

ME

1

Guatemala

1

Jordan

1

Netherlands

1

Luxembourg

2. List of Neoprofen drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8415337 RECORDATI RARE Ibuprofen compositions and methods of making same
Mar, 2032

(8 years from now)

Do you want to check out NEOPROFEN patents from before 2022?

Drugs and Companies using IBUPROFEN LYSINE ingredient

Market Authorisation Date: 13 April, 2006

Treatment: NA

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of NEOPROFEN before it's patent expiration?
More Information on Dosage

3. List of Signifor drug patents

Can you believe SIGNIFOR received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8299209 RECORDATI RARE Pharmaceutical composition comprising cyclic somatostatin analogues
Dec, 2025

(2 years from now)

US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(3 years from now)

Do you want to check out SIGNIFOR patents from before 2022?

Drugs and Companies using PASIREOTIDE DIASPARTATE ingredient

Market Authorisation Date: 14 December, 2012

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

SIGNIFOR family patents

9

United States

4

European Union

3

United Kingdom

3

Norway

3

Korea, Republic of

3

Australia

2

Spain

2

Austria

2

Hong Kong

2

Malaysia

2

Denmark

2

Germany

2

China

2

Russia

2

Poland

2

Brazil

2

Canada

2

Argentina

2

Japan

2

New Zealand

2

Cyprus

2

Peru

2

Israel

2

Portugal

2

Taiwan

2

Mexico

2

Ecuador

2

South Africa

2

Slovenia

1

Iceland

1

Czech Republic

1

Morocco

1

Croatia

1

Belgium

1

Chile

1

Slovakia

1

Colombia

1

Luxembourg

1

Tunisia

1

Hungary

4. List of Signifor Lar Kit drug patents

Can you believe SIGNIFOR LAR KIT received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7473761 RECORDATI RARE Somatostatin analogues
Dec, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822637 RECORDATI RARE Somatostatin analogues
Aug, 2023

(2 months from now)

US7759308 RECORDATI RARE Microparticles comprising somatostatin analogues
Oct, 2026

(3 years from now)

US9351923 RECORDATI RARE Extended-release composition comprising a somatostatin derivative in microparticles
May, 2028

(4 years from now)

Do you want to check out SIGNIFOR LAR KIT patents from before 2022?
Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 29, 2025

Drugs and Companies using PASIREOTIDE PAMOATE ingredient

Market Authorisation Date: 15 December, 2014

Treatment: Method of treating acromegaly

Dosage: FOR SUSPENSION;INTRAMUSCULAR

More Information on Dosage

SIGNIFOR LAR KIT family patents

11

United States

8

European Union

5

Korea, Republic of

4

Norway

4

Australia

3

Spain

3

Malaysia

3

Denmark

3

Poland

3

China

3

Brazil

3

Canada

3

Argentina

3

Japan

3

New Zealand

3

Peru

3

Israel

3

Portugal

3

Taiwan

3

Slovenia

3

Mexico

3

Ecuador

3

South Africa

3

United Kingdom

2

Hong Kong

2

Austria

2

Germany

2

Russia

2

Morocco

2

Cyprus

2

Luxembourg

2

Tunisia

2

Hungary

1

Uruguay

1

Panama

1

Dominican Republic

1

Iceland

1

Czech Republic

1

Ukraine

EA

1

EA

1

ME

1

Nicaragua

1

Croatia

1

Honduras

1

San Marino

1

Belgium

1

Guatemala

1

Chile

1

El Salvador

1

Georgia

1

Cuba

1

Costa Rica

1

Slovakia

1

Colombia

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic